11:33 AM
 | 
Mar 31, 2017
 |  BC Week In Review  |  Company News  |  Deals

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea via a separate private placement at the IPO price. Akcea’s pipeline comprises lipid disorder candidates volanesorsen, AKCEA-APO(a)-LRx,

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >